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Summary
Introduction:  Ramsay  Hunt  syndrome  is  a  viral  infection  that  combines  facial  palsy  and  pinnal
vesicular rash.
Objectives:  To  detail  diagnostic  criteria,  treatment  and  prognosis  in  Ramsay  Hunt  syndrome.
Patients  and  methods:  A  retrospective  study  of  15  patients  with  Ramsay  Hunt  syndrome  admit-
ted to  the  ENT  department  of  La  Rabta  Hospital  (Tunis)  from  2003  to  2009.
Results: The  main  presenting  symptom  was  facial  palsy  associated  with  conchal  vesicular  rash.
House-Brackmann  classiﬁcation  of  facial  nerve  function  ranged  from  III  to  V.  All  patients  were
treated with  acyclovir  and  corticosteroids.  Mean  follow-up  was  8  months.  Ten  patients  showed
improvement  in  facial  palsy,  four  had  permanent  palsy  and  one  moved  from  grade  IV  to  grade
III.
Conclusion:  Ramsay  Hunt  syndrome  involves  severe  dysfunction,  with  poorer  facial  nerve  prog-
nosis than  in  Bell’s  palsy.
© 2011  Published  by  Elsevier  Masson  SAS.
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n  1907,  J.  Ramsay  Hunt  described  a  syndrome  associating
acial  palsy,  inner  ear  dysfunction,  pinnal  pain  and  vesicular
ash  [1].
Now  referred  to  as  Ramsay  Hunt  syndrome,  it  is  a  rare
ause  of  facial  palsy,  possibly  originating  in  resurgence  of
aricella-zoster  virus  (VZV)  present  in  the  geniculate  gan-
lion  from  the  ﬁrst  infestation,  although  many  authors  have
uestioned  this  theory  [2].
Treatment  is  empiric;  several  drugs  have  been  reported,
ncluding  corticosteroids,  vasodilators,  vitamins  and  antivi-
al  agents.
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oi:10.1016/j.anorl.2011.08.003The  present  study  describes  the  clinical  presentation,
iagnosis,  treatment  and  prognosis  of  this  rare  but  severe
omplication  of  herpes  zoster.
atients and methods
 retrospective  study  included  15  of  the  30  Ramsay  Hunt
atients  managed  in  the  ENT  department  of  the  Rabta  Uni-
ersity  Hospital  Center  of  Tunis  (Tunisia)  over  a  7-year  period
2003—2009).  Unusable  ﬁles  and  patients  lost  to  follow-up
ere  excluded.  Diagnosis  was  clinical.
esultsight  men  and  seven  women,  mean  age  46  years  (range,
2—75  yrs),  consulted  at  a  mean  8  days  (range,  2—21  days)
fter  symptom  onset.  Four  patients  had  been  exposed  to
.
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Figure  1  Vesicular  lesions  of  the  concha.
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of  pinnal  herpes  zoster.
Diagnosis  is  founded  on  clinical  history  and  physical
examination  [8].  This  was  the  case  in  all  the  present  series.
Table  1  House-Brackmann  facial  nerve  function  grading
system  before  and  after  treatment.
Baseline  facial  nerve
function
Facial  nerve  function
after  treatment
Total
I II III IV  V
III  1  0  0  0  0  1
IV 4 2  1  1  0  8
V 0  3  0  0  3  6
Total 5  5  1  1  3  15cold  during  the  days  preceding  onset.  The  main  presenting
symptom  was  in  all  cases  facial  asymmetry  associated  with
conchal  vesicular  rash.  Thirteen  patients  had  associated
otalgia.  Nine  showed  partial  hearing  loss,  with  rotational
vertigo  and  unstable  gait  in  four  cases.  Two  patients  pre-
sented  with  herpes  zoster  of  the  V3  territory.
Clinical  examination  found  peripheral  facial  palsy  with
muscular  test  ranging  from  1/30  to  18/30  (mean,  7/30)  or
III  to  V  on  the  House-Brackmann  grading  system  [3].  Vesicular
lesions  of  the  ipsilateral  Ramsay-Hunt  region  were  observed
in  all  patients,  and  founded  diagnosis  (Fig.  1).  Neurovestibu-
lar  examination  found  harmonious  vestibular  syndrome  in
four  cases.
Systematic  audiography  found  unilateral  perception
hearing  loss  in  11  patients,  with  a  mean  threshold  of  55  dB
(range,  30—90  dB).  Stapedial  reﬂex  was  absent  ipsilaterally
to  the  facial  palsy  in  all  cases.
Caloric  test,  performed  in  the  four  patients  with  ver-
tigo,  showed  hyporeﬂexia  in  three  cases  and  areﬂexia  in  the
fourth.
All  patients  received  per  os  acyclovir  (Zovirax®)  antiviral
treatment  and  high-dose  corticosteroids  by  general  route
for  a  mean  8  days.  They  had  also  undergone  motor  physio-
therapy  and  received  local  care  for  the  pinnal  lesions.  Five
underwent  brain  and  internal  auditory  canal  MRI  at  a  mean
30  days  after  diagnosis,  revealing  facial  neuritis  in  four  cases
(Fig.  2).
Over  a  mean  follow-up  of  8  months  (range,  3  to
48  months),  facial  palsy  improved  in  10  patients,  with  test
scores  of  20  to  30/30  and  grades  I  or  II;  in  four  patients,
palsy  remained  stable  (grade  IV  or  V)  and  one  patient  showed
improvement  from  grade  IV  to  grade  III  (Table  1).
Cochleovestibular  evolution  showed  persistent  vertigo  in
one  patient  at  7  months’  FU  and  persistent  perception  hea-
ring  loss  in  six  patients.  Three  of  the  other  patients  showed
improvement  in  vertigo  and  ﬁve  in  hearing  loss,  with  mean
perception  hearing  loss  of  35  dB  (range,  25—40  dB)  on  control
audiogram.igure  2  Axial  T1-weighted  MRI:  strong  contrast  uptake  in  the
ight intratemporal  facial  nerve.
iscussion
tic  involvement  in  herpes  zoster  viral  infection  is  impli-
ated  in  12%  of  cases  of  peripheral  facial  palsy  [4].  Latent
ZV  infection  is  reactivated  in  the  geniculate  ganglion,  caus-
ng  otalgia,  pinnal  vesicular  rash  and  peripheral  facial  palsy.
It  is  a  rare  pathology,  with  an  incidence  of  5/100,000  per
ear;  nevertheless,  it  is  the  second  most  frequent  etiology
n  non-traumatic  peripheral  facial  palsy  [5].
Prognosis  for  facial  palsy  is  poorer  in  Ramsay  Hunt  syn-
rome  than  in  idiopathic  forms  [6].  Only  10%  of  patients  with
omplete  facial  palsy  are  totally  cured  [4].
Facial  nerve  involvement  is  initially  due  to  inﬂammation
aused  by  the  viral  neuronitis  and  secondarily  to  the  facial
erve  edema  [1,7].
Strictly,  Ramsay  Hunt  syndrome  is  deﬁned  as  facial  palsy
ith  associated  erythematovesicular  rash  of  the  pinna  or
outh.  Possible  involvement  of  Corti’s  (hearing  loss)  or
carpa’s  (vertigo)  ganglions  completes  the  total  otic  form
e24  R.  Zainine  et  al.
Table  2  Therapeutic  protocols  in  management  of  Ramsay  Hunt  syndrome.
Series  Corticosteroids  Dose  Route  Antiviral  Dose  Route
Uri  et  al.  [13]  Hydrocortisone  100  mg  ×  3/d  IV  Acyclovir  5  mg/kg/8h  IV
Murakami et  al.  [15]  Prednisolone  1  mg/kg/d  PO  Acyclovir  800  mg  ×5/d  PO
Kinishi et  al.  [14]  Methylprednisolone  500  mg/da IV  Acyclovir  800  mg  ×5/d  PO
Yeo et  al.  [11]  Prednisolone  1  mg/kg/d  PO  AcyclovirFamciclovir  5mg/kg/8  h500mg/db IV  PO
Present series  Hydrocortisone  100  mg  ×  3/d  IV  Acyclovir  800  mg  ×5/d  PO
PO: per os; IV: intravenous.
a Methylprednisolone 500 mg/d the 1st day, then 250 mg/d the 2nd and 3rd days, and 100 mg/d the last 4 days.
b Acyclovir for 5 days, then Famciclovir 500 mg/d for 7 days.
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[adolinium-enhanced  MRI  and  CSF  analysis  have  no  diagnos-
ic  or  prognostic  value  [9].
The  natural  history  of  pinnal  Ramsay  Hunt  syndrome
as  described  in  a  retrospective  study  of  102  non-treated
atients  [10]: facial  nerve  functional  impairment  reached  a
aximum  in  the  ﬁrst  week.
A  retrospective  study  [11]  of  81  treated  patients,  inclu-
ing  55  cases  of  Bell’s  palsy  and  26  of  Ramsay  Hunt  syn-
rome,  found  recovery  from  palsy,  with  House-Brackmann
rades  of  I  or  II  in  96.3%  of  Bell’s  palsy  cases  and  in  84.6%
f  palsies  associated  with  Ramsay  Hunt  syndrome.  Advanced
ge,  elevated  arterial  blood  pressure,  vertigo  and  diabetes
ere  factors  of  poor  prognosis  in  Ramsay  Hunt  syndrome.
The  neural  edema  in  a  narrow  space  in  the  Fallopian
anal  or  internal  auditory  canal  induces  neural  compres-
ion  and  hypoxia,  exacerbating  the  neural  degeneration.  The
owerful  anti-edematous  action  of  corticosteroids  has  been
linically  conﬁrmed:  high-dose  corticosteroids  is  one  of  the
ecognized  treatments  for  Ramsay  Hunt  syndrome  [12].
The  classical  high-dose  corticosteroid  treatment  for
amsay  Hunt  syndrome  has  been  changed  by  the  advent  of
ew  virostatic  agents,  notably  acyclovir,  which  has  an  effec-
ive  virostatic  action  on  herpes  group  viruses  by  interference
ith  DNA  polymerase  and  inhibition  of  replication.  Results
re  best  with  early  administration  [13]. In  the  present  series,
ll  patients  received  an  association  of  per  os  acyclovir
nd  high-dose  injected  corticosteroids,  resulting  in  clear
mprovement  in  10  of  the  15  patients  (Table  2).
Kinishi  et  al.  [14]  compared  isolated  corticotherapy  (47
atients)  and  associated  acyclovir  and  high-dose  injected
orticosteroids  (91  patients).  Prognosis  was  signiﬁcantly  bet-
er  in  the  latter  group,  with  good  nervous  function  and
mproved  recovery  rate.
Acyclovir  is  administered  at  15  mg/kg  per  day.  As  diges-
ive  tract  absorption  concerns  only  15—20%  of  the  ingested
ose,  higher  doses  are  recommended  in  per  os  delivery:
00  mg  per  os  ﬁve  times  daily  for  7—10  days  in  adults  [15].
There  was  no  signiﬁcant  difference  in  prognosis  according
o  per  os  versus  i.v.  administration  [15].
Murakami  et  al.  [15], in  a  large  retrospective  series
f  80  patients,  found  signiﬁcant  improvement  with  associ-
ted  acyclovir  and  prednisone  administered  within  3  days
f  symptom  onset.  Recovery  was  complete  in  75%  of
atients  treated  with  three  days,  compared  to  only  30%
f  those  treated  after  7  days.  This  suggests  that  early
[iagnosis  and  management  improves  prognosis  in  Ramsay
unt  syndrome.
onclusion
amsay  Hunt  syndrome  is  one  of  the  least  frequent  causes
f  facial  palsy,  inducing  severe  dysfunction  and  of  poorer
rognosis  for  the  facial  nerve  than  Bell’s  palsy.
Associated  acyclovir  and  high-dose  corticosteroids
mproves  facial  nerve  functional  recovery.
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